Study finds encouraging results in psilocybin treatment for TRD patients
Mental Health Weekly January 10, 2025 DOI: 10.1002/mhw.34292 via OpenAlex
Summary
AI-generated from the abstractIn an open-label study of patients with severe treatment-resistant depression, synthetic psilocybin produced significant decreases in depressive symptoms. The treatment also showed significant safety and efficacy for this population.
Study at a glance
| Characteristics | Open-label study Peer reviewed |
|---|---|
| Population | Patients with severe treatment resistant depression |
| Intervention | Synthetic psilocybin |
| Topics | Psilocybin |
| Keywords | Psychology Medicine Hallucinogen |
| Key finding | Synthetic psilocybin significantly reduced depressive symptoms and demonstrated safety and efficacy in patients with severe treatment-resistant depression. |
Abstract
Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depressive symptoms. Researchers of the open‐label study also found significant safety and efficacy of synthetic psilocybin in TRD patients.